Laddar...
A fresh perspective on comparing the FDA and the CHMP/EMA: approval of antineoplastic tyrosine kinase inhibitors
We compared and determined the reasons for any differences in the review and approval times of tyrosine kinase inhibitors (TKIs) by the US Food and Drug Administration (FDA) and the European EMA/CHMP. Applications for these novel cancer drugs were submitted to them within a mean of 31.2 days of each...
Sparad:
| Huvudupphovsmän: | , , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Blackwell Science Inc
2013
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3769667/ https://ncbi.nlm.nih.gov/pubmed/23362829 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12085 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|